Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer

Grants

Funding Acknowledgements

This programme was funded by AstraZeneca. J. Lewis and P. Carpenter are employees of AstraZeneca. None of the other authors has been recompensed for time involved in evaluating and reporting these data. However, B. Solomon, M. J. Peters and J. J. Bowden have received honoraria for Continuing Medical Education presentations and B. Solomon and M. J. Peters have previously served on Advisory Boards in relation to gefitinib.